CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells

Cancer Immunology, Immunotherapy

Volumn 60, Issue 6, 2011, Pages 781-792

  Olson, Brian M ^a   McNeel, Douglas G ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Androgen receptor ligand binding domain (AR LBD); CD8+ T cell clone; CTL; Epitope; Polyfunctional cytokine expression

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR 761; ANDROGEN RECEPTOR 805; ANDROGEN RECEPTOR 811; CANCER VACCINE; MONENSIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNIZATION; LIGAND BINDING; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HLA-DR1 ANTIGEN; HUMANS; LIGANDS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79959735058     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0987-5     Document Type: Article

References (45)

1. DR Berthold GR Pond F Soban R de Wit M Eisenberger IF Tannock 2008 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2 242 245
2. IF Tannock R de Wit WR Berry J Horti A Pluzanska KN Chi S Oudard C Theodore ND James I Turesson MA Rosenthal MA Eisenberger 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 1502 1512 (Pubitemid 39315317)
3. PW Kantoff TJ Schuetz BA Blumenstein LM Glode DL Bilhartz M Wyand K Manson DL Panicali R Laus J Schlom WL Dahut PM Arlen JL Gulley WR Godfrey 2010 Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 7 1099 1105
4. CS Higano PF Schellhammer EJ Small PA Burch J Nemunaitis L Yuh N Provost MW Frohlich 2009 Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 16 3670 3679
5. DG McNeel EJ Dunphy JG Davies TP Frye LE Johnson MJ Staab DL Horvath J Straus D Alberti R Marnocha G Liu JC Eickhoff G Wilding 2009 Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer J Clin Oncol 27 25 4047 4054
6. MA Cheever JP Allison AS Ferris OJ Finn BM Hastings TT Hecht I Mellman SA Prindiville JL Viner LM Weiner LM Matrisian 2009 The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 15 17 5323 5337
7. MH Andersen IM Svane JC Becker PT Straten 2007 The universal character of the tumor-associated antigen survivin Clin Cancer Res 13 20 5991 5994 (Pubitemid 350075053)
8. B Acres JM Limacher 2005 MUC1 as a target antigen for cancer immunotherapy Expert Rev Vaccines 4 4 493 502 (Pubitemid 41297296)
9. CN Baxevanis NN Sotiriadou AD Gritzapis PA Sotiropoulou SA Perez NT Cacoullos M Papamichail 2006 Immunogenic HER-2/neu peptides as tumor vaccines Cancer Immunol Immunother 55 1 85 95 (Pubitemid 41783298)
10. ML Disis KH Grabstein PR Sleath MA Cheever 1999 Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin Cancer Res 5 6 1289 1297 (Pubitemid 29282931)
11. C Swanton A Futreal T Eisen 2006 Her2-targeted therapies in non-small cell lung cancer Clin Cancer Res 12 14 Pt 2 4377s 4383s (Pubitemid 44197185)
12. A Scardino D Gross P Alves J Schultze S Graff-Dubois O Faure S Tourdot S Chouaib L Nadler F Lemmonnier R Bonderheide A Cardoso K Kosmatopoulos 2002 HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy J Immunol 168 5900 5906 (Pubitemid 34556179)
13. GL Beatty RH Vonderheide 2008 Telomerase as a universal tumor antigen for cancer vaccines Expert Rev Vaccines 7 7 881 887
14. Q Yang KM Fung WV Day BP Kropp HK Lin 2005 Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival Cancer Cell Int 5 1 8
15. J Edwards NS Krishna KM Grigor JM Bartlett 2003 Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer Br J Cancer 89 3 552 556 (Pubitemid 37026442)
16. CW Gregory KG Hamil D Kim SH Hall TG Pretlow JL Mohler FS French 1998 Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes Cancer Res 58 24 5718 5724 (Pubitemid 29006412)
17. N Sharifi WL Farrar 2006 Androgen receptor as a therapeutic target for androgen independent prostate cancer Am J Ther 13 2 166 170
18. L Bubendorf J Kononen P Koivisto P Schraml H Moch TC Gasser N Willi MJ Mihatsch G Sauter OP Kallioniemi 1999 Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays Cancer Res 59 4 803 806 (Pubitemid 29086730)
19. CA Heinlein C Chang 2004 Androgen receptor in prostate cancer Endocr Rev 25 2 276 308 (Pubitemid 38501396)
20. MP Steinkamp OA O'Mahony M Brogley H Rehman EW Lapensee S Dhanasekaran MD Hofer R Kuefer A Chinnaiyan MA Rubin KJ Pienta DM Robins 2009 Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy Cancer Res 69 10 4434 4442
21. E Jager M Ringhoffer M Altmannsberger M Arand J Karback D Jager F Oesch A Knuth 1997 Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma Int J Cancer 71 2 142 147 (Pubitemid 27252981)
22. E Ranieri LS Kierstead H Zarour JM Kirkwood MT Lotze T Whiteside WJ Storkus 2000 Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading Immunol Invest 29 2 121 125 (Pubitemid 30316952)
23. S Wojtowicz-Praga UN Verma L Wakefield JM Esteban D Hartmann A Mazumder 1996 Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2 J Immunother Emphasis Tumor Immunol 19 3 169 175 (Pubitemid 26234610)
24. H Schreiber TH Wu J Nachman WM Kast 2002 Immunodominance and tumor escape Semin Cancer Biol 12 1 25 31 (Pubitemid 34087895)
25. FM Marincola EM Jaffee DJ Hicklin S Ferrone 2000 Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Adv Immunol 74 181 273
26. A Riker J Cormier M Panelli U Kammula E Wang A Abati P Fetsch KH Lee S Steinberg S Rosenberg F Marincola 1999 Immune selection after antigen-specific immunotherapy of melanoma Surgery 126 2 112 120 (Pubitemid 29382769)
27. CL Slingluff Jr TA Colella L Thompson DD Graham JC Skipper J Caldwell L Brinckerhoff DJ Kittlesen DH Deacon C Oei NL Harthun EL Huczko DF Hunt TL Darrow VH Engelhard 2000 Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens Cancer Immunol Immunother 48 12 661 672 (Pubitemid 30146461)
28. B Gottlieb LK Beitel JH Wu M Trifiro 2004 The androgen receptor gene mutations database (ARDB): 2004 update Hum Mutat 23 6 527 533 (Pubitemid 38720602)
29. R Hu TA Dunn S Wei S Isharwal RW Veltri E Humphreys M Han AW Partin RL Vessella WB Isaacs GS Bova J Luo 2009 Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res 69 1 16 22
30. BM Olson DG McNeel 2007 Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer Prostate 67 16 1729 1739 (Pubitemid 350228725)
31. S Sauma M Gammon M Bednarek B Cunningham W Biddison J Hermes G Porter S Tamhankar J Hawkins B Bush, et al. 1993 Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein Hum Immunol 37 4 252 258 (Pubitemid 23343714)
32. BM Olson TP Frye LE Johnson L Fong KL Knutson ML Disis DG McNeel 2010 HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase Cancer Immunol Immunother 59 6 943 953
33. A Pajot ML Michel N Fazilleau V Pancre C Auriault DM Ojcius FA Lemonnier YC Lone 2004 A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice Eur J Immunol 34 11 3060 3069 (Pubitemid 39549385)
34. A Johannsen R Genolet DF Legler SA Luther IF Luescher 2010 Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice J Immunol 185 6 3445 3455
35. K Parker M Bednarek J Coligan 1994 Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains J Immunol 152 163
36. HG Rammensee T Friede S Stevanoviic 1995 MHC ligands and peptide motifs: first listing Immunogenetics 41 4 178 228
37. DG McNeel LD Nguyen WJ Ellis CS Higano PH Lange ML Disis 2001 Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer Prostate 47 3 222 229 (Pubitemid 32378374)
38. H Rammensee J Bachmann NP Emmerich OA Bachor S Stevanovic 1999 SYFPEITHI: database for MHC ligands and peptide motifs Immunogenetics 50 3-4 213 219 (Pubitemid 30099526)
39. S Zhang H Zhang J Zhao 2009 The role of CD4 T cell help for CD8 CTL activation Biochem Biophys Res Commun 384 4 405 408
40. MG Duvall ML Precopio DA Ambrozak A Jaye AJ McMichael HC Whittle M Roederer SL Rowland-Jones RA Koup 2008 Polyfunctional T cell responses are a hallmark of HIV-2 infection Eur J Immunol 38 2 350 363
41. ML Precopio MR Betts J Parrino DA Price E Gostick DR Ambrozak TE Asher DC Douek A Harari G Pantaleo R Bailer BS Graham M Roederer RA Koup 2007 Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses J Exp Med 204 6 1405 1416 (Pubitemid 46919878)
42. GA Rizzuto T Merghoub D Hirschhorn-Cymerman C Liu AM Lesokhin D Sahawneh H Zhong KS Panageas MA Perales G Altan-Bonnet JD Wolchok AN Houghton 2009 Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response J Exp Med 206 4 849 866
43. RA Seder PA Darrah M Roederer 2008 T-cell quality in memory and protection: implications for vaccine design Nat Rev Immunol 8 4 247 258 (Pubitemid 351432801)
44. J Yuan S Gnjatic H Li S Powel HF Gallardo E Ritter GY Ku AA Jungbluth NH Segal TS Rasalan G Manukian Y Xu RA Roman SL Terzulli M Heywood E Pogoriler G Ritter LJ Old JP Allison JD Wolchok 2008 CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit Proc Natl Acad Sci USA 105 51 20410 20415
45. MC Feltkamp MP Vierboom WM Kast CJ Melief 1994 Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity Mol Immunol 31 18 1391 1401 (Pubitemid 24381796)